TY - JOUR T1 - Pulmonary arterial hypertension in patients treated with interferon JF - European Respiratory Journal JO - Eur Respir J SP - 1851 LP - 1853 DO - 10.1183/13993003.01376-2015 VL - 46 IS - 6 AU - Laurent Savale AU - Marie-Camille Chaumais AU - Olivier Sitbon AU - Marc Humbert Y1 - 2015/12/01 UR - http://erj.ersjournals.com/content/46/6/1851.abstract N2 - We read with interest the correspondence by Prella and colleagues reporting yet another case of pulmonary arterial hypertension (PAH) suspected to be induced by long-term interferon (IFN)-β therapy in a patient with multiple sclerosis. As discussed by Prella and colleagues, IFN-α and IFN-β are regarded as “possible” risk factors for PAH [1]. This was justified by the publication of case reports of IFN-induced PAH in the past decade [2–10] and the experience recently reported by the French Referral Centre for Pulmonary Hypertension [11]. Despite strong clinical and temporal suspicion, it remains a great challenge to definitively confirm the causal role of IFN in the development PAH because many patients (especially those treated with IFN-α for hepatitis C) have concomitant PAH risk factors such as portal hypertension and/or HIV infection. In these patients, IFN therapy may potentially act as an additional trigger for portopulmonary and/or HIV-associated PAH.Accumulating clinical and experimental data argue for a possible causal link between IFN therapy and PAH http://ow.ly/Ttsqv ER -